Literature DB >> 26872481

TRPV1 channel as a target for cancer therapy using CNT-based drug delivery systems.

Andres Ortega-Guerrero1, John M Espinosa-Duran2, Jaime Velasco-Medina3.   

Abstract

Carbon nanotubes are being considered for the design of drug delivery systems (DDSs) due to their capacity to internalize molecules and control their release. However, for cellular uptake of drugs, this approach requires an active translocation pathway or a channel to transport the drug into the cell. To address this issue, it is suggested to use TRPV1 ion channels as a potential target for drug release by nano-DDSs since these channels are overexpressed in cancer cells and allow the permeation of large cationic molecules. Considering these facts, this work presents three studies using molecular dynamics simulations of a human TRPV1 (hTRPV1) channel built here. The purpose of these simulations is to study the interaction between a single-wall carbon nanotube (SWCNT) and hTRPV1, and the diffusion of doxorubicin (DOX) across hTRPV1 and across a POPC lipid membrane. The first study shows an attractive potential between the SWCNT surface and hTRPV1, tilting the adsorbed SWCNT. The second study shows low diffusion probability of DOX across the open hTRPV1 due to a high free energy barrier. Although, the potential energy between DOX and hTRPV1 reveals an attractive interaction while DOX is inside hTRPV1. These results suggest that if the channel is dilated, then DOX diffusion could occur. The third study shows a lower free energy barrier for DOX across the lipid membrane than for DOX across hTRPV1. Taking into account the results obtained, it is feasible to design novel nano-DDSs based on SWCNTs to accomplish controlled drug release into cells using as translocation pathway, the hTRPV1 ion channel.

Entities:  

Keywords:  Carbon nanotubes; Doxorubicin; Drug delivery system; Molecular dynamics; TRPV1 channel

Mesh:

Substances:

Year:  2016        PMID: 26872481     DOI: 10.1007/s00249-016-1111-8

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  55 in total

Review 1.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

2.  How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system?

Authors:  Uthumporn Arsawang; Oraphan Saengsawang; Thanyada Rungrotmongkol; Purinchaya Sornmee; Kitiyaporn Wittayanarakul; Tawun Remsungnen; Supot Hannongbua
Journal:  J Mol Graph Model       Date:  2010-11-11       Impact factor: 2.518

Review 3.  Applications of carbon nanotubes in drug delivery.

Authors:  Alberto Bianco; Kostas Kostarelos; Maurizio Prato
Journal:  Curr Opin Chem Biol       Date:  2005-10-17       Impact factor: 8.822

Review 4.  Emerging implications of nanotechnology on cancer diagnostics and therapeutics.

Authors:  Alex G Cuenca; Huabei Jiang; Steven N Hochwald; Matthew Delano; William G Cance; Stephen R Grobmyer
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

5.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

6.  Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation.

Authors:  Chiu-Wing Lam; John T James; Richard McCluskey; Robert L Hunter
Journal:  Toxicol Sci       Date:  2003-09-26       Impact factor: 4.849

Review 7.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

8.  Toxicity of single walled carbon nanotubes to rainbow trout, (Oncorhynchus mykiss): respiratory toxicity, organ pathologies, and other physiological effects.

Authors:  Catherine J Smith; Benjamin J Shaw; Richard D Handy
Journal:  Aquat Toxicol       Date:  2007-02-11       Impact factor: 4.964

9.  Pharmacodynamics of TRPV1 agonists in a bioassay using human PC-3 cells.

Authors:  Daniel Alvarez-Berdugo; Marcel Jiménez; Pere Clavé; Laia Rofes
Journal:  ScientificWorldJournal       Date:  2014-02-02

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  4 in total

1.  Effect of drug amlodipine on the charged lipid bilayer cell membranes DMPS and DMPS + DMPC: a molecular dynamics simulation study.

Authors:  Abbas Yousefpour; Sepideh Amjad-Iranagh; Fatemeh Goharpey; Hamid Modarress
Journal:  Eur Biophys J       Date:  2018-07-03       Impact factor: 1.733

Review 2.  Inflammation, Cancer and Immunity-Implication of TRPV1 Channel.

Authors:  Joanna Katarzyna Bujak; Daria Kosmala; Iwona Monika Szopa; Kinga Majchrzak; Piotr Bednarczyk
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

3.  Improved gliotransmission by increasing intracellular Ca2+ via TRPV1 on multi-walled carbon nanotube platforms.

Authors:  Won-Seok Lee; Ji-Hye Kang; Jung-Hwan Lee; Yoo Sung Kim; Jongmin Joseph Kim; Han-Sem Kim; Hae-Won Kim; Ueon Sang Shin; Bo-Eun Yoon
Journal:  J Nanobiotechnology       Date:  2022-08-11       Impact factor: 9.429

Review 4.  Calcium Entry through TRPV1: A Potential Target for the Regulation of Proliferation and Apoptosis in Cancerous and Healthy Cells.

Authors:  Kevin Zhai; Alena Liskova; Peter Kubatka; Dietrich Büsselberg
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.